Eli Lilly plans to introduce its weight-loss pill, orforglipron, in India, offering a non-injectable alternative that may appeal to patients wary of injections. Orforglipron belongs to the GLP-1 drug class, which curbs appetite and mirrors the mechanism of Lilly’s successful injectables Mounjaro and Zepbound. Though not yet approved anywhere globally, Lilly intends to seek regulatory clearance in the U.S., UK, EU, Japan, and China.
Recent trials show orforglipron outperforms Novo Nordisk’s Rybelsus in lowering blood sugar and weight among Type-2 diabetes patients. Lilly India’s president, Winselow Tucker, expressed optimism about the drug’s potential in India, citing cultural and logistical resistance to injectables. Despite these challenges, demand for injectable GLP-1 drugs such as Wegovy and Mounjaro have surged in India.
Last updated: December 26th, 2025
